Bolt Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	17.75	7.21	10.81	9.24	27.38	5.54
Short-Term Investments	14.16	40.12	91.38	159.64	158.84	17.3
Cash & Short-Term Investments	31.91	47.32	102.19	168.89	186.22	22.84
Cash Growth	-40.69%	-53.69%	-39.49%	-9.31%	715.39%	-34.42%
Other Receivables	0.95	0.81	0.6	-	-	-
Receivables	0.95	0.81	0.6	-	-	-
Prepaid Expenses	1.96	1.84	2.74	3.86	2.94	2.52
Restricted Cash	0.78	0.78	-	-	-	-
Other Current Assets	-	0.06	0.18	-	-	-
Total Current Assets	35.61	50.81	105.71	172.75	189.16	25.36
Property, Plant & Equipment	21.38	24.9	24.08	28.53	30.6	16.35
Long-Term Investments	6.91	22.88	26.41	23.94	85.35	-
Long-Term Deferred Charges	-	0.05	0.37	-	-	2.36
Other Long-Term Assets	1.16	0.99	3.22	2.59	2.61	2.47
Total Assets	65.05	99.63	159.78	227.81	307.72	46.54
Accounts Payable	1.52	1.51	2.99	3.59	3.57	1.6
Accrued Expenses	3.84	8.34	12.49	15.14	12.38	6.66
Current Portion of Leases	2.7	2.25	2.78	2.39	2.5	1.5
Current Unearned Revenue	1.91	3.02	2.2	1.99	2.87	1.5
Other Current Liabilities	-	0.74	-	-	-	-
Total Current Liabilities	9.97	15.86	20.46	23.12	21.33	11.26
Long-Term Leases	20.89	22.96	17.44	20.22	21.85	9.38
Long-Term Unearned Revenue	1.96	3.62	9.11	12.92	14.21	-
Other Long-Term Liabilities	0.13	-	0.04	0.04	0.21	0.33
Total Liabilities	32.95	42.43	47.04	56.3	57.6	20.97
Additional Paid-In Capital	486.26	484.5	476.99	467.51	457.43	3.45
Retained Earnings	-454.15	-427.4	-364.29	-295.09	-206.99	-108.4
Comprehensive Income & Other	-0.01	0.1	0.04	-0.92	-0.32	-
Total Common Equity	32.1	57.2	112.74	171.51	250.12	-104.95
Shareholders' Equity	32.1	57.2	112.74	171.51	250.12	25.57
Total Liabilities & Equity	65.05	99.63	159.78	227.81	307.72	46.54
Total Debt	23.59	25.21	20.22	22.61	24.36	10.88
Net Cash (Debt)	8.32	22.11	81.97	146.28	161.86	11.96
Net Cash Growth	-76.64%	-73.02%	-43.96%	-9.63%	1253.27%	-51.46%
Net Cash Per Share	4.34	11.58	43.36	78.31	97.52	113.79
Filing Date Shares Outstanding	1.92	1.92	1.91	1.89	1.87	1.82
Total Common Shares Outstanding	1.92	1.92	1.91	1.89	1.87	0.11
Working Capital	25.64	34.96	85.25	149.63	167.83	14.1
Book Value Per Share	16.72	29.84	59.16	90.75	133.75	-985.35
Tangible Book Value	32.1	57.2	112.74	171.51	250.12	-104.95
Tangible Book Value Per Share	16.72	29.84	59.16	90.75	133.75	-985.35
Machinery	8.27	10.13	10.42	10.1	8.26	5.32
Leasehold Improvements	0.36	0.29	0.29	0.27	0.15	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q